Atopic Dermatitis Epidemiology Forecast - 2034
Description
Key Highlights
Atopic dermatitis, also called eczema, is a multifaceted, chronic relapsing inflammatory skin disease commonly associated with other atopic manifestations such as food allergy, allergic rhinitis, and asthma.
It is the most common type of skin inflammation that usually starts in early childhood but can occur at any age and can be recurrent or persistent throughout life.
Pruritus is an essential feature of atopic dermatitis, and the diagnosis of active atopic dermatitis cannot be made without a history of itching. However, although pruritus is a cardinal symptom of atopic dermatitis, its mechanism and association with the cutaneous nervous system are not completely understood.
Currently, no specific test for atopic dermatitis exists, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of atopic dermatitis is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.
In 2024, the total number of prevalent cases of atopic dermatitis across the 7MM was approximately 73 million, the numbers are anticipated to increase by 2034.
Atopic dermatitis demonstrates a clear age-related prevalence pattern, with higher rates observed in children compared to adults. In 2024, across the 7MM, approximately 25 million prevalent cases were reported in individuals under 18 years of age, while around 48 million cases were recorded in adults aged 18 and older.
In 2024, EU4 and the UK accounted for approximately 22 million diagnosed cases of atopic dermatitis.
Among severity-specific cases, mild atopic dermatitis accounted for the majority of diagnosed cases in the United States in 2024, representing approximately 60% of the total.
It is a highly prevalent and heterogeneous condition that imposes a substantial clinical and economic burden across age groups and geographies. Its early onset, chronic nature, and frequent comorbidities underscore the need for continued research, improved diagnostic tools, and personalized treatment strategies to enhance patient outcomes and quality of life.
DelveInsight’s “Atopic dermatitis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of atopic dermatitis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Atopic Dermatitis: Disease Understanding
Atopic Dermatitis Overview, and Diagnosis
Atopic dermatitis, also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood but can occur at any age and can be recurrent or persistent throughout life. In ‘dermatitis,’ ‘derm’ means ‘skin,’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness, and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies; it is the most common chronic skin disease in children.
The diagnosis is based on signs and symptoms; other diseases that must be excluded before diagnosis include contact dermatitis, psoriasis, and seborrheic dermatitis. It can significantly impact the quality of life, not just that of the patient, but also of family and friends. The itch can make concentrating difficult, and poor sleep can make people feel like zombies during the day. Also, treatments and precautions can take a toll on time, energy, and money. The condition usually improves or clears up if the substance causing the problem is identified and avoided.
The primary symptom of atopic dermatitis is dry, itchy skin that often turns into a red rash; during a flare, atopic dermatitis becomes a red, itchy rash. Many different physical and internal factors can trigger an eczema flare-up. The resulting inflammation causes increased blood flow and the urge to itch. Eczema flares are part of the agonizing itch-scratch cycle that is hard to fight, leading to more inflammation and even skin infections.
No specific test for atopic dermatitis exists, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Atopic dermatitis diagnosis is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis
Atopic Dermatitis Epidemiology
The Atopic dermatitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases, age-specific prevalent cases, total diagnosed prevalent cases, severity-specific cases, and gender-specific cases of Atopic dermatitis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
In 2024, the total number of prevalent atopic dermatitis cases in the United States was approximately 33 million, driven by increasing environmental triggers, rising allergy rates, and greater awareness leading to more frequent diagnoses.
In 2024, the total number of prevalent atopic dermatitis cases in the EU4 and the UK was approximately 9 million in individuals under 18 years of age and about 21 million in those aged 18 years and older.
In 2024, among the severity-specific cases of atopic dermatitis in the EU4 and the UK, moderate cases accounted for approximately 9 million.
In 2024, gender-specific data from Japan indicated that the total number of diagnosed prevalent cases of atopic dermatitis was approximately 3 million in males and 4 million in females.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the American Social Health Association, US; Dartmouth Institute for Health Policy and Clinical Practice, US; Institute for Medical Virology, Germany; Centre Médicale de l'Institut Pasteur, France; University of Genova, Italy; University of Barcelona, Spain; Kyushu University, Fukuoka, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of atopic dermatitis, explaining its causes, signs and symptoms, pathogenesis, and current diagnosis methods.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Atopic Dermatitis Report Insights
Patient Population
Country-wise Epidemiology Distribution
Atopic Dermatitis Report Key Strengths
Ten-year Forecast
The 7MM Coverage
Atopic dermatitis Epidemiology Segmentation
Atopic Dermatitis Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of Atopic dermatitis? What will be the growth opportunities across the 7MM concerning the patient population pertaining to atopic dermatitis?
What is the historical and forecasted atopic dermatitis patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of atopic dermatitis?
Which clinical factors will affect atopic dermatitis?
Which factors will affect the increase in the diagnosis of Atopic dermatitis?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in Atopic dermatitis cases in varying geographies over the coming years.
A detailed overview of total prevalent cases, total diagnosed prevalent cases, age-specific cases, severity-specific cases, and gender-specific cases is included.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Atopic dermatitis, also called eczema, is a multifaceted, chronic relapsing inflammatory skin disease commonly associated with other atopic manifestations such as food allergy, allergic rhinitis, and asthma.
It is the most common type of skin inflammation that usually starts in early childhood but can occur at any age and can be recurrent or persistent throughout life.
Pruritus is an essential feature of atopic dermatitis, and the diagnosis of active atopic dermatitis cannot be made without a history of itching. However, although pruritus is a cardinal symptom of atopic dermatitis, its mechanism and association with the cutaneous nervous system are not completely understood.
Currently, no specific test for atopic dermatitis exists, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of atopic dermatitis is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.
In 2024, the total number of prevalent cases of atopic dermatitis across the 7MM was approximately 73 million, the numbers are anticipated to increase by 2034.
Atopic dermatitis demonstrates a clear age-related prevalence pattern, with higher rates observed in children compared to adults. In 2024, across the 7MM, approximately 25 million prevalent cases were reported in individuals under 18 years of age, while around 48 million cases were recorded in adults aged 18 and older.
In 2024, EU4 and the UK accounted for approximately 22 million diagnosed cases of atopic dermatitis.
Among severity-specific cases, mild atopic dermatitis accounted for the majority of diagnosed cases in the United States in 2024, representing approximately 60% of the total.
It is a highly prevalent and heterogeneous condition that imposes a substantial clinical and economic burden across age groups and geographies. Its early onset, chronic nature, and frequent comorbidities underscore the need for continued research, improved diagnostic tools, and personalized treatment strategies to enhance patient outcomes and quality of life.
DelveInsight’s “Atopic dermatitis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of atopic dermatitis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Atopic Dermatitis: Disease Understanding
Atopic Dermatitis Overview, and Diagnosis
Atopic dermatitis, also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood but can occur at any age and can be recurrent or persistent throughout life. In ‘dermatitis,’ ‘derm’ means ‘skin,’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness, and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies; it is the most common chronic skin disease in children.
The diagnosis is based on signs and symptoms; other diseases that must be excluded before diagnosis include contact dermatitis, psoriasis, and seborrheic dermatitis. It can significantly impact the quality of life, not just that of the patient, but also of family and friends. The itch can make concentrating difficult, and poor sleep can make people feel like zombies during the day. Also, treatments and precautions can take a toll on time, energy, and money. The condition usually improves or clears up if the substance causing the problem is identified and avoided.
The primary symptom of atopic dermatitis is dry, itchy skin that often turns into a red rash; during a flare, atopic dermatitis becomes a red, itchy rash. Many different physical and internal factors can trigger an eczema flare-up. The resulting inflammation causes increased blood flow and the urge to itch. Eczema flares are part of the agonizing itch-scratch cycle that is hard to fight, leading to more inflammation and even skin infections.
No specific test for atopic dermatitis exists, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Atopic dermatitis diagnosis is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis
Atopic Dermatitis Epidemiology
The Atopic dermatitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases, age-specific prevalent cases, total diagnosed prevalent cases, severity-specific cases, and gender-specific cases of Atopic dermatitis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
In 2024, the total number of prevalent atopic dermatitis cases in the United States was approximately 33 million, driven by increasing environmental triggers, rising allergy rates, and greater awareness leading to more frequent diagnoses.
In 2024, the total number of prevalent atopic dermatitis cases in the EU4 and the UK was approximately 9 million in individuals under 18 years of age and about 21 million in those aged 18 years and older.
In 2024, among the severity-specific cases of atopic dermatitis in the EU4 and the UK, moderate cases accounted for approximately 9 million.
In 2024, gender-specific data from Japan indicated that the total number of diagnosed prevalent cases of atopic dermatitis was approximately 3 million in males and 4 million in females.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the American Social Health Association, US; Dartmouth Institute for Health Policy and Clinical Practice, US; Institute for Medical Virology, Germany; Centre Médicale de l'Institut Pasteur, France; University of Genova, Italy; University of Barcelona, Spain; Kyushu University, Fukuoka, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of atopic dermatitis, explaining its causes, signs and symptoms, pathogenesis, and current diagnosis methods.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Atopic Dermatitis Report Insights
Patient Population
Country-wise Epidemiology Distribution
Atopic Dermatitis Report Key Strengths
Ten-year Forecast
The 7MM Coverage
Atopic dermatitis Epidemiology Segmentation
Atopic Dermatitis Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of Atopic dermatitis? What will be the growth opportunities across the 7MM concerning the patient population pertaining to atopic dermatitis?
What is the historical and forecasted atopic dermatitis patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of atopic dermatitis?
Which clinical factors will affect atopic dermatitis?
Which factors will affect the increase in the diagnosis of Atopic dermatitis?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in Atopic dermatitis cases in varying geographies over the coming years.
A detailed overview of total prevalent cases, total diagnosed prevalent cases, age-specific cases, severity-specific cases, and gender-specific cases is included.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
60 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Epidemiology and Market Methodology
- 4. Atopic Dermatitis Epidemiology at a Glance
- 4.1. Patient Share (%) Distribution of Atopic Dermatitis in 2024
- 4.2. Patient Share (%) Distribution of Atopic Dermatitis in 2034
- 5. Executive Summary
- 5.1. Key Events
- 6. Disease Background and Overview
- 6.1. Signs and Symptoms
- 6.2. Causes and Triggers
- 6.3. Clinical Presentation
- 6.4. Pathophysiology
- 6.5. Skin Hypersensitivity – Abnormalities of the Cell Layer
- 6.5.1. Mechanisms involved in inflammation
- 6.5.2. Pruritus
- 6.5.2.1. Pathophysiology of pruritus in Atopic Dermatitis
- 6.5.2.2. Alarmins and neuropeptides
- 6.6. Differential Diagnosis
- 6.7. Diagnosis
- 6.7.1. Diagnostic Criteria for Eczema
- 6.7.2. Diagnosis Guidelines
- 6.7.3. Diagnostic Algorithm
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumption and Rationale
- 7.2.1. United States
- 7.2.2. EU4 and the UK
- 7.2.3. Japan
- 7.3. Total Prevalent Cases of Atopic Dermatitis in the 7MM
- 7.4. Epidemiology Scenario in the US
- 7.4.1. Total Prevalent Cases Of Atopic Dermatitis in the US
- 7.4.2. Age-specific Prevalent Cases Of Atopic Dermatitis in the US
- 7.4.3. Total Diagnosed Prevalent Cases Of Atopic Dermatitis in the US
- 7.4.4. Severity-specific cases of atopic dermatitis in the US
- 7.4.5. Gender-specific cases of atopic dermatitis in the US
- 7.5. Epidemiology Scenario in EU4 and the UK
- 7.5.1. Total Prevalent Cases of Atopic Dermatitis in EU4 and the UK
- 7.5.2. Age-specific Prevalent Cases Of Atopic Dermatitis in the EU4 and the UK
- 7.5.3. Total Diagnosed Prevalent Cases Of Atopic Dermatitis in the EU4 and the UK
- 7.5.4. Severity-specific Cases Of Atopic Dermatitis in the EU4 and the UK
- 7.5.5. Gender-specific Cases Of Atopic Dermatitis in the EU4 and the UK
- 7.6. Epidemiology Scenario in Japan
- 7.6.1. Total Prevalent Cases of Atopic Dermatitis in Japan
- 7.6.2. Age-specific Prevalent Cases Of Atopic Dermatitis in Japan
- 7.6.3. Total Diagnosed Prevalent Cases Of Atopic Dermatitis in Japan
- 7.6.4. Severity-specific Cases Of Atopic Dermatitis in in Japan
- 7.6.5. Gender-specific Cases Of Atopic Dermatitis in Japan
- 8. KOL Views
- 9. Appendix
- 9.1. Acronyms and Abbreviations
- 9.2. Bibliography
- 9.3. Report Methodology
- 10. DelveInsight Capabilities
- 11. Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
